Adlinameg Tablet 2.5 mg + 500 mg is a combination oral antidiabetic medication containing Linagliptin 2.5 mg and Metformin Hydrochloride 500 mg. It is formulated for the management of type 2 diabetes mellitus in adults who are not achieving adequate glycemic control with lifestyle modifications alone or require combination therapy for better blood sugar management.

This dual-action tablet provides a convenient option for patients, combining two complementary mechanisms in a single pill. Adlinameg helps regulate blood glucose levels, improve insulin sensitivity, and reduce postprandial glucose excursions. It should be used as part of a comprehensive diabetes management plan that includes diet, exercise, and regular monitoring.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Composition

• Linagliptin 2.5 mg

• Metformin Hydrochloride 500 mg

Mechanism of Action

Adlinameg combines the glucose-lowering effects of a DPP-4 inhibitor and a biguanide to provide effective glycemic control:

Linagliptin
Linagliptin inhibits dipeptidyl peptidase-4 (DPP-4), an enzyme that degrades incretin hormones (GLP-1 and GIP). By increasing incretin levels, it enhances glucose-dependent insulin secretion and suppresses glucagon release after meals, improving postprandial blood glucose control.

Metformin Hydrochloride
Metformin primarily reduces hepatic glucose production (gluconeogenesis) and enhances peripheral insulin sensitivity, promoting glucose uptake in muscle and fat tissues. Unlike insulin secretagogues, metformin does not increase insulin secretion, lowering the risk of hypoglycemia when used alone.

The combination of these two mechanisms provides comprehensive blood glucose control, addressing both impaired insulin response and excessive glucose production.

Indications

Adlinameg Tablet 2.5 mg + 500 mg is indicated for:

• Management of Type 2 Diabetes Mellitus in adults

• Patients inadequately controlled with diet, exercise, or monotherapy with either linagliptin or metformin

• Combination therapy to achieve improved glycemic control

• Use alongside lifestyle modifications to reduce long-term complications of diabetes

Benefits

• Dual Mechanism of Action: Addresses both insulin insufficiency and excessive glucose production

• Effective HbA1c Reduction: Helps maintain long-term glycemic control

• Improves Fasting and Postprandial Glucose: Supports stable blood sugar levels throughout the day

• Low Risk of Hypoglycemia: Especially when not combined with insulin or sulfonylureas

• Weight Neutral: Linagliptin does not contribute to weight gain, and metformin may aid modest weight reduction

• Convenient Single Tablet Therapy: Enhances treatment adherence by combining two agents

  রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Dosage and Administration

Adlinameg Tablet 2.5 mg + 500 mg is usually taken once or twice daily with meals to reduce gastrointestinal side effects associated with metformin. The exact dosage should be determined by a healthcare professional based on the patient’s glycemic response, renal function, and tolerance.

Patients should maintain adequate hydration and continue routine monitoring of blood glucose, HbA1c, and kidney function during therapy.

Safety and Precautions

• Not suitable for Type 1 diabetes or diabetic ketoacidosis

• Use with caution in patients with renal or hepatic impairment

• Metformin may cause mild gastrointestinal discomfort, nausea, or diarrhea, especially at the start of therapy

• Rare risk of lactic acidosis exists; seek immediate medical attention if severe fatigue, abdominal pain, or breathing difficulties occur

• Linagliptin may rarely cause mild headache or nasopharyngitis

• Patients should inform their healthcare provider about all medications and medical conditions before starting therapy.